NEW YORK (GenomeWeb) – CombiMatrix today announced the New York State Department of Health (NYSDOH) has granted the firm conditional approval for its array-based test for pre-implantation genetic screening (PGS).
The CombiPGS test is intended for women undergoing pre-implantation genetic screening for chromosomal abnormalities during in vitro fertilization.
"The demand for our CombiPGS test across the country has been strong since our launch in early 2015," CombiMatrix CEO Mark McDonough said in a statement. "We are very excited to now offer this service in New York State, which ranks second only to California in the total number of IVF cycles performed nationally each year." He added that the firm offers per-embryo pricing for PGS testing.
McDonough also said that the firm hired two sales representatives in New York this year. "We have been successful driving our test adoption in the New York market for miscarriage analysis and we see a high potential for growth with CombiPGS," he said.
The Irvine, California-based molecular diagnostics firm received conditional approval from NYSDOH for its CombiSNP array for pre-natal diagnosis in August.